What other stocks do shareholders of AdAlta own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AdAlta investors own include Macquarie Group (MQG) , Magellan Financial Group (MFG) , Medlab Clinical (MDC) , iRhythm Technologies (IRTC) , FBR (FBR) , Embark Early Education (EVO) , Dacian Gold (DCN) , Constellation Technologies (CT1) , Afterpay (APT) .

ASX:1AD

AdAlta (1AD) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free 1AD Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 135,957 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get AdAlta alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About AdAlta Stock (ASX:1AD)

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics by its i-body platform in Australia. Its lead product is AD-214, an antibody therapeutic, which is in Phase I clinical trial for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis and interstitial lung disease, kidney fibrosis, eye fibrosis, and various cancers. AdAlta Limited has collaborative partnerships with GE Healthcare to develop i-body enabled granzyme B PET imaging agents for use in immuno-oncology; and Carina Biotech to develop CAR-T cell products against various solid tumor antigens. The company was incorporated in 2006 and is based in Bundoora, Australia.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

1AD Stock News Headlines

April 8, 2024 | msn.com

Long Shortz with AdAlta: Strengthening bonds in the fight against cancer

April 7, 2024 | msn.com

AdAlta and SYNthesis BioVentures collaborate on advanced cell-based cancer immunotherapy

April 19, 2024 | TradeSmith (Ad)

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

March 8, 2024 | finance.yahoo.com

AdAlta delivers positive Phase I Extension Study results for AD-214

March 8, 2024 | msn.com

ScoPo’s (actually Wilkie’s) Powerplays: Health stocks rise as AdAlta soars 17% on trial results

February 15, 2024 | bbc.com

Leeds - Weather warnings issued

February 11, 2024 | msn.com

Countdown on to AdAlta trial results as biotech advances partner discussions

February 4, 2024 | finance.yahoo.com

AdAlta Insiders Placed Bullish Bets Worth AU$850.2k

April 19, 2024 | TradeSmith (Ad)

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

January 22, 2024 | msn.com

AdAlta advancing partnering programs as AD-214 participants receive final dose

January 9, 2024 | es.investing.com

Adalta Ltd (1AD)

January 4, 2024 | msn.com

What’s in store for 2024: AdAlta

December 28, 2023 | msn.com

Money Talks: Keep an eye on these tasty precious metal and biotech plays in 2024

December 19, 2023 | msn.com

Long Shortz with AdAlta: How the company has potentially broken the malaria life cycle

December 18, 2023 | msn.com

‘World first’: AdAlta’s i-body platform a breakthrough for malaria treatment

December 13, 2023 | msn.com

AdAlta on track for trial readout in Q1 2024 after $1.65m cap raise

November 30, 2023 | msn.com

‘Best place we’ve ever been’: AdAlta looks to monetise lead asset in 2024

November 20, 2023 | msn.com

ASX Health Stocks: Painchek’s Europe patent accepted; and HeraMed signs deal with Telstra Health

November 20, 2023 | msn.com

AdAlta’s latest results bolster safety profile and dose selection for primary asset, enhancing partnering, reducing Phase 2 trial risks

November 18, 2023 | proactiveinvestors.com.au

AdAlta raises $1.65 million in oversubscribed placement to support clinical study and partner discussions

November 15, 2023 | finance.yahoo.com

It's Probably Less Likely That AdAlta Limited's (ASX:1AD) CEO Will See A Huge Pay Rise This Year

November 7, 2023 | proactiveinvestors.com.au

AdAlta closes oversubscribed $1.65 million raise

October 22, 2023 | proactiveinvestors.com.au

AdAlta making material progress on partnering talks

October 19, 2023 | au.investing.com

AdAlta to present lead product AD-214 at MPGPCR 2023 pharmacology conference

October 17, 2023 | proactiveinvestors.com.au

AdAlta receives $2.3 million FY23 R&D refund; extends loan repayment terms

September 26, 2023 | finance.yahoo.com

AdAlta says new AD-214 dosing models enhance partnering potential

September 24, 2023 | proactiveinvestors.com.au

AdAlta clinical dose simulations of AD-214 support target intravenous dose regime

See More Headlines

Receive 1AD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AdAlta and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:1AD
CUSIP: N/A
CIK: N/A
Web: www.adalta.com.au
Phone: 61 3 9479 5159
Fax: N/A
Employees: 10
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-5,040,000.00
Net Margins: -144.13%
Pretax Margin: N/A
Return on Equity: -196.58%
Return on Assets: -48.37%

Debt

Debt-to-Equity Ratio: 82.91
Current Ratio: 1.83
Quick Ratio: 2.84

Sales & Book Value

Annual Sales: $3.50 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 1.94
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 525,810,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.67

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Timothy Charles Oldham B.Sc.
BSc(Hons), L.L.B., LLB(Hons), Ph.D., CEO, MD & Director
Mr. Angus Tester Ph.D.
Senior Director of Operations
Ms. Janette Dixon
Head of Business Development
Mr. Cameron Jones C.A.
Company Secretary

Key Competitors

View All Competitors

Insiders

1AD Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of AdAlta own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AdAlta investors own include Macquarie Group (MQG), Magellan Financial Group (MFG), Medlab Clinical (MDC), iRhythm Technologies (IRTC), FBR (FBR), Embark Early Education (EVO), Dacian Gold (DCN), Constellation Technologies (CT1), Afterpay (APT).

This page (ASX:1AD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial